Not recruitingISRCTN44218911

A multicentre, parallel group, study of ethyl-eicosapentaenoate (ethyl-EPA) in people with schizophrenia

This study is not recruiting in the United Kingdom. It is testing ethyl-eicosapentaenoate (ethyl-EPA) for schizophrenia.

Schizophrenia, Mental healthOtherOver 18 Years

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Compensation and expense reimbursement have not been verified for this summary.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateNot clearly listed

Recruitment status: Not recruiting
Enrollment listed in the registry: Not clearly listed
Sponsor: Laxdale Ltd (UK)
Sponsor type: Other organization
Study type: Other
Intervention type: Other / unclear
Study phase: Not clearly listed
Locations: United Kingdom
Age range: Over 18 Years
Official registry ID: ISRCTN44218911
Official title: A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: ISRCTN44218911. We help you review the study, but cannot decide medical eligibility.

Not recruiting

United Kingdom

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Laxdale Ltd (UK).

Who can participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.